Judah Frommer
Stock Analyst at Morgan Stanley
(3.07)
# 1,307
Out of 4,711 analysts
177
Total ratings
58.91%
Success rate
5.48%
Average return
Main Sectors:
Stocks Rated by Judah Frommer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| FDMT 4D Molecular Therapeutics | Initiates: Underweight | $8 | $6.31 | +26.78% | 1 | Nov 21, 2024 | |
| APLS Apellis Pharmaceuticals | Initiates: Equal-Weight | $31 | $33.21 | -6.65% | 1 | Nov 21, 2024 | |
| RGNX REGENXBIO | Assumes: Overweight | $22 | $7.62 | +188.71% | 1 | Nov 15, 2024 | |
| ACLX Arcellx | Maintains: Overweight | $81 → $106 | $75.54 | +40.32% | 2 | Nov 6, 2024 | |
| BCAX Bicara Therapeutics | Initiates: Overweight | $35 | $17.59 | +98.98% | 1 | Oct 8, 2024 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $38 | $26.76 | +42.00% | 2 | Apr 22, 2024 | |
| MURA Mural Oncology | Initiates: Overweight | $13 | $3.18 | +308.81% | 1 | Apr 4, 2024 | |
| PROK ProKidney | Assumes: Equal-Weight | $3 | $1.51 | +98.68% | 1 | Mar 7, 2024 | |
| JSPR Jasper Therapeutics | Reiterates: Outperform | $40 | $21.57 | +85.44% | 8 | Aug 14, 2023 | |
| ABOS Acumen Pharmaceuticals | Reiterates: Outperform | $13 | $1.85 | +602.70% | 5 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $30 | $31.82 | -5.72% | 8 | Aug 9, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $11.68 | +96.92% | 5 | Aug 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $50 | $46.24 | +8.13% | 9 | Jul 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $141 | $118.97 | +18.52% | 13 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $13 | $1.55 | +738.71% | 5 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $9 | $1.19 | +656.30% | 5 | May 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $21 → $22 | $25.50 | -13.73% | 2 | Apr 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $8 → $7 | $8.75 | -20.00% | 3 | Mar 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $11 → $8 | $4.35 | +83.91% | 5 | Mar 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $14.60 | +215.07% | 5 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $6.5 → $7 | $2.19 | +219.63% | 6 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $51 → $55 | $16.98 | +223.91% | 3 | Feb 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $46 | $70.44 | -34.70% | 1 | Feb 24, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $47 → $49 | $84.39 | -41.94% | 4 | Nov 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $328 → $370 | $954.07 | -61.22% | 2 | Oct 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $24 → $31 | $67.69 | -54.20% | 6 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $65 → $76 | $76.97 | -1.26% | 8 | Sep 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Neutral | $182 | $76.40 | +138.22% | 9 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $107 | $72.94 | +46.70% | 15 | Aug 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $90 → $95 | $117.91 | -19.43% | 10 | Jul 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $19.52 | -7.79% | 1 | Jul 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $93 → $116 | $106.08 | +9.35% | 15 | Jun 10, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $31 → $38 | $93.77 | -59.48% | 4 | May 22, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $18 → $22 | $131.70 | -83.30% | 1 | May 6, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $33 → $35 | $61.85 | -43.41% | 9 | Apr 29, 2020 |
4D Molecular Therapeutics
Nov 21, 2024
Initiates: Underweight
Price Target: $8
Current: $6.31
Upside: +26.78%
Apellis Pharmaceuticals
Nov 21, 2024
Initiates: Equal-Weight
Price Target: $31
Current: $33.21
Upside: -6.65%
REGENXBIO
Nov 15, 2024
Assumes: Overweight
Price Target: $22
Current: $7.62
Upside: +188.71%
Arcellx
Nov 6, 2024
Maintains: Overweight
Price Target: $81 → $106
Current: $75.54
Upside: +40.32%
Bicara Therapeutics
Oct 8, 2024
Initiates: Overweight
Price Target: $35
Current: $17.59
Upside: +98.98%
Galapagos NV
Apr 22, 2024
Maintains: Equal-Weight
Price Target: $38
Current: $26.76
Upside: +42.00%
Mural Oncology
Apr 4, 2024
Initiates: Overweight
Price Target: $13
Current: $3.18
Upside: +308.81%
ProKidney
Mar 7, 2024
Assumes: Equal-Weight
Price Target: $3
Current: $1.51
Upside: +98.68%
Jasper Therapeutics
Aug 14, 2023
Reiterates: Outperform
Price Target: $40
Current: $21.57
Upside: +85.44%
Acumen Pharmaceuticals
Aug 9, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.85
Upside: +602.70%
Aug 9, 2023
Reiterates: Outperform
Price Target: $30
Current: $31.82
Upside: -5.72%
Aug 8, 2023
Reiterates: Outperform
Price Target: $23
Current: $11.68
Upside: +96.92%
Jul 20, 2023
Reiterates: Neutral
Price Target: $50
Current: $46.24
Upside: +8.13%
Jun 23, 2023
Reiterates: Neutral
Price Target: $141
Current: $118.97
Upside: +18.52%
May 16, 2023
Reiterates: Outperform
Price Target: $13
Current: $1.55
Upside: +738.71%
May 12, 2023
Reiterates: Outperform
Price Target: $9
Current: $1.19
Upside: +656.30%
Apr 3, 2023
Maintains: Outperform
Price Target: $21 → $22
Current: $25.50
Upside: -13.73%
Mar 31, 2023
Maintains: Outperform
Price Target: $8 → $7
Current: $8.75
Upside: -20.00%
Mar 10, 2023
Downgrades: Neutral
Price Target: $11 → $8
Current: $4.35
Upside: +83.91%
Mar 7, 2023
Reiterates: Outperform
Price Target: $46
Current: $14.60
Upside: +215.07%
Mar 7, 2023
Upgrades: Neutral
Price Target: $6.5 → $7
Current: $2.19
Upside: +219.63%
Feb 28, 2023
Maintains: Outperform
Price Target: $51 → $55
Current: $16.98
Upside: +223.91%
Feb 24, 2023
Reiterates: Outperform
Price Target: $46
Current: $70.44
Upside: -34.70%
Nov 5, 2020
Maintains: Outperform
Price Target: $47 → $49
Current: $84.39
Upside: -41.94%
Oct 6, 2020
Maintains: Neutral
Price Target: $328 → $370
Current: $954.07
Upside: -61.22%
Sep 21, 2020
Maintains: Outperform
Price Target: $24 → $31
Current: $67.69
Upside: -54.20%
Sep 21, 2020
Maintains: Outperform
Price Target: $65 → $76
Current: $76.97
Upside: -1.26%
Aug 6, 2020
Assumes: Neutral
Price Target: $182
Current: $76.40
Upside: +138.22%
Aug 6, 2020
Assumes: Outperform
Price Target: $107
Current: $72.94
Upside: +46.70%
Jul 22, 2020
Maintains: Neutral
Price Target: $90 → $95
Current: $117.91
Upside: -19.43%
Jul 21, 2020
Initiates: Outperform
Price Target: $18
Current: $19.52
Upside: -7.79%
Jun 10, 2020
Maintains: Outperform
Price Target: $93 → $116
Current: $106.08
Upside: +9.35%
May 22, 2020
Maintains: Outperform
Price Target: $31 → $38
Current: $93.77
Upside: -59.48%
May 6, 2020
Maintains: Neutral
Price Target: $18 → $22
Current: $131.70
Upside: -83.30%
Apr 29, 2020
Maintains: Neutral
Price Target: $33 → $35
Current: $61.85
Upside: -43.41%